Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.57 |
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | JAK2 | O60674 | 2/20 | 0.54 |
| ▸ | JAK3 | P52333 | 2/20 | 0.54 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.54 |
| ▸ | CA2 | P00918 | 2/20 | 0.53 |
| ▸ | CCR2 | P41597 | 1/20 | 0.51 |
| ▸ | NOS3 | P29474 | 1/20 | 0.50 |
| ▸ | NOS1 | P29475 | 1/20 | 0.50 |
| ▸ | NOS2 | P35228 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11123197 | 0.83 | CA2 (0.64) | HRH3SMN1; SMN2LMNAALDH1A1MAPT | |
| SCHEMBL8236801 | 0.83 | HRH3 (0.64) | HRH3LMNAALDH1A1CCR2CYP2D6 | |
| SCHEMBL3920768 | 0.83 | HRH3 (0.56) | HRH3SMN1; SMN2LMNAALDH1A1MAPT | |
| SCHEMBL15467001 | 0.82 | HRH3 (0.87) | HRH3SMN1; SMN2LMNAALDH1A1MAPT | |
| SCHEMBL979381 | 0.81 | LMNA (0.52) | LMNAKCNJ1CCR2 | |
| SCHEMBL22516895 | 0.81 | CCR2 (0.59) | LMNAALDH1A1KCNJ1JAK2JAK3 | |
| SCHEMBL722275 | 0.80 | SIGMAR1 (0.56) | HRH3LMNACCR2MEN1KMT2A | |
| SCHEMBL19392475 | 0.79 | TSHR (0.69) | HRH3SMN1; SMN2LMNAALDH1A1TSHR | |
| Hydrochloric Acid SCHEMBL29045124 | 0.79 | CXCR4 (0.57) | HRH3LMNACCR2MEN1KMT2A | |
| SCHEMBL14375228 | 0.79 | HRH3 (0.65) | HRH3SMN1; SMN2LMNAJAK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1635829-A1 | 8-(3-BIARYL)PHENYLQUINOLINE PHOSPHODIESTERASE-4-INHIBITORS | Merck Frosst Canada Ltd. (CA) | 2006-03-22 | — | — | EP | claimed |
| WO-2004096220-A1 | 8-(3-BIARYL)PHENYLQUINOLINE PHOSPHODIESTERASE-4-INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2004-11-11 | — | — | WO | claimed |
| US-20140086936-A1 | MATRIPTASE INHIBITORS AND USES THEREOF AGAINST ORTHOMYXOVIRIDAE INFECTIONS | SOCPRA Sciences Sante et Humaines S.E.C. (CA) | 2014-03-27 | — | — | US | disclosed |
| EP-1635829-A1 | 8-(3-BIARYL)PHENYLQUINOLINE PHOSPHODIESTERASE-4-INHIBITORS | Merck Frosst Canada Ltd. (CA) | 2006-03-22 | — | — | EP | disclosed |
| WO-2004096220-A1 | 8-(3-BIARYL)PHENYLQUINOLINE PHOSPHODIESTERASE-4-INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2004-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140086936-A1 | MATRIPTASE INHIBITORS AND USES THEREOF AGAINST ORTHOMYXOVIRIDAE INFECTIONS | MMP7, MATR3, ADAMTS1 | HRH3 1813/4885SMN1; SMN2 2353/4885LMNA 3507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.